Fireside Chat, Interview
Talks at GS – Nick Leschly: The Promise of Gene Therapy
- Bluebird Bio aims to leverage genetic manipulation to correct underlying disease causes, focusing its technology on restoring lost biological functions and engineering new immune functions to attack cancer and autoimmune diseases while explicitly excluding non-life-threatening cosmetic applications.
- The company plans to pursue a thoughtful development pipeline to avoid the regulatory shutdowns that previously halted gene therapy progress in the United States for five to ten years, anticipating potential early patient setbacks but targeting a one-time potentially curative treatment for sickle cell disease that could last a patient's lifetime and benefit hundreds of thousands of individuals.
- Technical strategies include using crippled HIV viruses as delivery mechanisms to insert DNA into cells, ablating existing marrow to remove competition, and engineering cells to identify and expand to eliminate tumors, with the expectation that treated cells will naturally home and function indefinitely without ongoing maintenance.
- Expected clinical outcomes for sickle cell disease include the potential for patients to discontinue pain medication like Advil within six months of the procedure, representing a significant milestone building upon the science of the previous 30 to 50 years.
- Organizational culture is built on the dual foundation of "True Blue" (happiness and transition) and "Blue Mojo" (competitive determination), reinforced by a "paranoid" mindset inspired by the principle that "only the paranoid survive" to ensure the team constantly focuses on "the next hill" without complacency.
- Leadership plans to maintain a culture where humility is prioritized through policies such as coach travel for all employees, the avoidance of fancy offices, and the integration of a sabbatical program designed to demonstrate work-life balance and authenticity.
- A capable team structure is expected to allow the CEO to take extended six-week leaves without negative operational consequences, although such separation may not be feasible during critical deal-making phases like high-stakes negotiations.
- The company intends to prevent failure by anchoring employee behavior in a core belief system regarding the mission rather than external factors like stock price fluctuations or physical office perks, ensuring that the organization remains patient-centric even as it navigates the "bumps" inherent in early-stage gene therapy.